Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity

The prevalence of obesity-induced type 2 diabetes (T2D) is increasing worldwide, and new treatment strategies are needed. We recently discovered that obesity activates a previously unknown pathway that promotes both excessive hepatic glucose production (HGP) and defective insulin signaling in hepato...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Diabetes
Egile Nagusiak: Ozcan, Lale, Xu, Xiaoming, Deng, Shi-Xian, Ghorpade, Devram S., Thomas, Tiffany, Cremers, Serge, Hubbard, Brian, Serrano-Wu, Michael H., Gaestel, Matthias, Landry, Donald W., Tabas, Ira
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Diabetes Association 2015
Gaiak:
Metabolism
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4587644/
https://ncbi.nlm.nih.gov/pubmed/26068544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db14-1945
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak